3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lung Neoplasms
4
Glioblastoma
3
Head and Neck Neoplasms
2
Glioma
2
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Rhabdomyosarcoma
1
Prostatic Neoplasms
1
Pheochromocytoma
1
Paraganglioma
1
Papillary renal cell carcinoma, sporadic
1
Pancreatic Neoplasms
1
Pancreatic Ductal Adenocarcinoma
1
Osteoradionecrosis
1
Neurotoxicity Syndromes
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mouth Neoplasms
1
Melanoma
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Hereditary leiomyomatosis and renal cell cancer
1
Hematopoietic and Lymphoid System Neoplasm
1
Healthy Volunteers
1
Gliosarcoma
1
Interventions
Paclitaxel
7
Oxaliplatin
6
Vincristine
4
Radiotherapy
4
Leucovorin
4
Carboplatin
4
Amifostine
4
Taxes
3
Sodium Chloride
3
Procarbazine
3
Methotrexate
3
Fluorouracil
3
Cytarabine
3
xaliproden
2
glucarpidase
2
Rituximab
2
Radiotherapy, Intensity-Modulated
2
Radiotherapy, Conformal
2
Prednisolone
2
Magnesium Sulfate
2
Duloxetine Hydrochloride
2
Dexamethasone
2
Cyclophosphamide
2
Cisplatin
2
Calcium Gluconate
2
Acupuncture Therapy
2
neurotropin
1
motexafin gadolinium
1
haloperidol decanoate
1
glutamic acid diethyl ester
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neurotoxicity Syndromes
×
Contrast Media
×
Clear all
NCT05510596
2024-08-09
MR-ICANS
University Hospital, Montpellier
Phase NA
Completed
25 enrolled